Securian Asset Management Inc. Increases Stock Holdings in Masimo Corporation (NASDAQ:MASI)

Securian Asset Management Inc. boosted its stake in Masimo Corporation (NASDAQ:MASI) by 3.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,433 shares of the medical equipment provider’s stock after purchasing an additional 100 shares during the quarter. Securian Asset Management Inc.’s holdings in Masimo were worth $572,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. FMR LLC lifted its position in Masimo by 19.8% during the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider’s stock valued at $1,338,509,000 after purchasing an additional 1,340,836 shares during the last quarter. Vanguard Group Inc. lifted its position in Masimo by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider’s stock valued at $758,182,000 after purchasing an additional 66,215 shares during the last quarter. Capital Research Global Investors lifted its position in Masimo by 80.5% during the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider’s stock valued at $405,807,000 after purchasing an additional 1,094,647 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Masimo by 119.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock valued at $286,823,000 after purchasing an additional 943,001 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its position in Masimo by 8.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,662,376 shares of the medical equipment provider’s stock valued at $274,791,000 after purchasing an additional 135,888 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Stock Down 0.7%

Shares of NASDAQ MASI opened at $158.35 on Friday. The company has a quick ratio of 1.62, a current ratio of 2.17 and a debt-to-equity ratio of 0.67. Masimo Corporation has a 52 week low of $101.61 and a 52 week high of $194.88. The firm’s fifty day moving average is $162.14 and its 200 day moving average is $166.04. The company has a market cap of $8.59 billion, a price-to-earnings ratio of -17.27 and a beta of 1.19.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 EPS for the quarter, topping the consensus estimate of $1.24 by $0.12. The business had revenue of $372.00 million during the quarter, compared to analyst estimates of $367.79 million. Masimo had a negative net margin of 25.06% and a positive return on equity of 22.56%. The company’s revenue for the quarter was down 24.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.77 EPS. On average, equities research analysts expect that Masimo Corporation will post 4.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. BTIG Research reiterated a “buy” rating on shares of Masimo in a research report on Monday. Piper Sandler reissued an “overweight” rating and set a $200.00 price target (down from $215.00) on shares of Masimo in a research note on Wednesday, May 7th. Raymond James Financial decreased their price target on shares of Masimo from $204.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Wells Fargo & Company decreased their price target on shares of Masimo from $205.00 to $190.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Thursday, April 10th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Masimo presently has a consensus rating of “Moderate Buy” and a consensus price target of $191.60.

Insider Transactions at Masimo

In other Masimo news, COO Bilal Muhsin sold 10,000 shares of the company’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $163.28, for a total transaction of $1,632,800.00. Following the transaction, the chief operating officer owned 24,172 shares in the company, valued at approximately $3,946,804.16. This represents a 29.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 9.70% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.